Posted inCardiology Diabetes & Endocrinology news
Beyond the LDL Receptor: Why ANGPTL3 Inhibition Is the New Gold Standard for Homozygous Familial Hypercholesterolemia
Clinical trials and meta-analyses demonstrate that ANGPTL3 inhibitors, including SHR-1918 and zodasiran, provide superior LDL-C reduction compared to PCSK9 inhibitors in HoFH, particularly in patients with null-receptor genotypes where traditional therapies often fail.